Search
for
Sort by
Research 91–120 of 1000+
- Patient-Reported Hair Loss and Its Impacts as Measured by the Alopecia Areata Patient Priority Outcomes Instrument in Patients Treated with Ritlecitinib: The ALLEGRO Phase 2b/3 Randomized Clinical Trial
- Hair transplantation in mice: Challenges and solutions
- Comparison of Trichoscopic Features of Alopecia Areata before and after Treatment with Intralesional Steroids
- Expanding the therapeutic landscape of minoxidil for androgenetic alopecia: topical, oral and sublingual formulations
- Oral cyclosporin does not arrest progression of androgenetic alopecia
- 42005 Sustained scalp, eyebrow, and eyelash hair regrowth with ritlecitinib through Week 48 in patients with alopecia areata: post hoc analysis of the ALLEGRO phase 2b/3 study
- Female pattern hair loss: current treatment concepts.
- Clinicopathologic Characteristics and Response to Treatment of Persistent Chemotherapy-Induced Alopecia in Breast Cancer Survivors
- Cyclosporine for moderate-to-severe alopecia areata: A double-blind, randomized, placebo-controlled clinical trial of efficacy and safety
- Androgenetic alopecia: new insights into the pathogenesis and mechanism of hair loss
- Location of keratin-associated proteins in developing fiber cuticle cells using immunoelectron microscopy
- Alopecia Areata–Specific Patient-Reported Outcome Measures
- Faculty Opinions recommendation of Therapeutic implications of topical cetirizine 1% in treatment of male androgenetic alopecia: A case-controlled study.
- Faculty Opinions recommendation of Distinguishing androgenetic alopecia from chronic telogen effluvium when associated in the same patient: a simple noninvasive method.
- Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considerations, and ethics
- Presence of mast cells and mast cell degranulation in scalp biopsies of telogen effluvium
- A multicentre cohort study of the clinicopathological features and treatment outcomes of fibrosing alopecia in a pattern distribution
- A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results
- Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial
- Trichodynia and telogen effluvium in COVID-19 patients: Results of an international expert opinion survey on diagnosis and management
- Refractory folliculitis decalvans treated with adalimumab: A case series of 23 patients
- Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)
- Telogen Effluvium
- Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO‐LT phase 3, open‐label study
- Sustained hair regrowth with continued ritlecitinib treatment through week 48 in patients with alopecia areata with or without early target responses: Post hoc analysis of the ALLEGRO phase 2b/3 trial
- Skin manifestations of polycystic ovary syndrome
- Real World Evidence in Alopecia Areata: Current Management, Emerging Therapies and Future Challenges – A Narrative Review
- Treatment of androgenetic alopecia in transgender people receiving testosterone therapy with sublingual minoxidil: A randomized, double-blind, placebo-controlled clinical trial
- Systemic Treatment of Moderate to Severe Alopecia Areata in Adults: Updated Australian Expert Consensus Statement
- Safety of Alopecia Treatments in Patients with Breast Cancer and High-Risk Women: A Review